Optimal Region of Lymph Node Dissection in Distal Pancreatectomy for Left-Sided Pancreatic Cancer Based on Tumor Location
- PMID: 34837132
- DOI: 10.1245/s10434-021-11108-5
Optimal Region of Lymph Node Dissection in Distal Pancreatectomy for Left-Sided Pancreatic Cancer Based on Tumor Location
Abstract
Background: The optimal lymph node (LN) dissection for left-sided pancreatic cancer based on tumor location has remained unknown. In particular, the efficacy of LN dissection around the common hepatic artery and the celiac axis for distal tumors has not been established. This study was designed to elucidate the frequency and prognostic impact of LN metastasis, focusing on tumor location.
Methods: Data from 110 patients with invasive pancreatic cancer who underwent distal pancreatectomy between 2007 and 2020 were collected. We used a quantitative value-the distance between the left side of the portal vein and the right side of tumor (DPT)-to define the tumor location. LN stations were divided into two groups: peripancreatic lymph nodes (PLN) and non-PLN. We then analyzed the frequency of LN metastasis based on the tumor location and prognostic factors.
Results: Non-PLN metastasis was observed in 7.3% of patients. Non-PLN metastasis was found only in patients with a DPT < 20 mm. Patients with non-PLN metastasis exhibited a significantly worse prognosis than those with only-PLN metastasis (median survival time: 20.3 vs. 42.5 months, p = 0.048). Multivariate analysis for survival indicated that tumor size > 4 cm (hazard ratio [HR]: 2.23, p = 0.012) and metastasis in the non-PLN region (HR: 3.02, p = 0.015), and inability to undergo adjuvant chemotherapy (HR: 2.81, p = 0.0018) were also associated with poor prognosis.
Conclusions: Dissection of the non-PLN region can be avoided in selected patients with DPT ≥ 20 mm.
© 2021. Society of Surgical Oncology.
Comment in
-
ASO Author Reflections: Optimal Region of Lymph Node Dissection in Distal Pancreatectomy for Pancreatic Cancer Based on Tumor Location: Should We Dissect Non-Peripancreatic Lymph Nodes for all Left-Sided Pancreatic Cancer Patients?Ann Surg Oncol. 2022 Apr;29(4):2425-2426. doi: 10.1245/s10434-021-11115-6. Epub 2022 Jan 7. Ann Surg Oncol. 2022. PMID: 34994895 No abstract available.
-
Lymph Node Regions of Consequence in Distal Pancreatectomy: Can We Be Selective By Tumor Location?Ann Surg Oncol. 2022 Apr;29(4):2150-2151. doi: 10.1245/s10434-021-11185-6. Epub 2022 Jan 14. Ann Surg Oncol. 2022. PMID: 35028794 No abstract available.
References
-
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654 . - DOI - PubMed
-
- Yeo CJ, Cameron JL, Sohn TA, et al. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg. 1999;229(5):613–24. https://doi.org/10.1097/00000658-199905000-00003 . - DOI - PubMed - PMC
-
- Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg. 2002;236(3):355. - DOI
-
- Farnell MB, Pearson RK, Sarr MG, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery. 2005;138(4):618–30. - DOI
-
- Nimura Y, Nagino M, Takao S, et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas. J Hepatobiliary Pancreat Sci. 2012;19(3):230–41. - DOI
MeSH terms
LinkOut - more resources
Full Text Sources
Medical